Transcriptional silencing of tumor suppressor genes by DNA methylation occurs in cancer
cell lines and in human tumors. This has led to the pursuit of DNA methyltransferase …

Epigenetic events, such as aberrant DNA methylation, have been demonstrated to silence
the expression of many genes that suppress malignancy. Since the event is reversible, it is …

The mechanism of action of DNA methylation inhibitor 5-aza-2′-deoxycytidine (5-aza-
CdR), a potential anticancer agent is believed to be activated by the demethylation of tumor …

Genome-wide DNA methylation patterns are frequently deregulated in cancer. There is
considerable interest in targeting the methylation machinery in tumor cells using nucleoside …

Epigenetic alterations are a hallmark of cancer that govern the silencing of genes. Up to
now, 5-azacytidine (5-aza-CR, Vidaza) and 5-aza-2′-deoxycytidine (5-aza-dC, Dacogen) …

DNA cytosine methylation plays a considerable role in normal development, gene
regulation, and carcinogenesis. Hypermethylation of the promoters of some tumor …

Background The inactivation of tumor suppressor genes (TSGs) by aberrant DNA
methylation plays an important role in the development of malignancy. Since this epigenetic …

The cytosine analog 5-aza-2′-deoxycytidine is a potent inhibitor of DNA methyltransferase.
Its cytotoxicity has been attributed to several possible mechanisms including reexpression of …

Azacytidine was first synthesized almost 40 years ago. It was demonstrated to have a wide
range of anti-metabolic activities when tested against cultured cancer cells and to be an …

DNA-demethylating agents activate tumor suppressor genes that are silenced by DNA
methylation in cancer and are therefore emerging as a novel approach to cancer therapy. 5 …